{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:04:32Z","timestamp":1767913472938,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.vaccine.2018.01.075","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T10:32:55Z","timestamp":1518517975000},"page":"1398-1404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine"],"prefix":"10.1016","volume":"36","author":[{"given":"Ki Wook","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoan Jong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Kyung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yae-Jean","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwang Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Ho","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.01.075_b0005","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.vaccine.2005.10.054","article-title":"The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine\u2013results from 30 years experience in Taiwan","volume":"24","author":"Yang","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0015","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/j.vaccine.2011.08.117","article-title":"Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO((R))","volume":"29","author":"Schuller","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12879-014-0744-4","volume":"15","author":"Yun","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.075_b0025","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0264-410X(02)00772-7","article-title":"Establishment of an analyzing method for a Japanese encephalitis virus neutralization test in Vero cells","volume":"21","author":"Abe","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0030","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.01.075_b0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/14712598.8.1.95","article-title":"Current use and development of vaccines for Japanese encephalitis","volume":"8","author":"Beasley","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2018.01.075_b0040","first-page":"303","article-title":"Development of Vero cell-derived inactivated Japanese encephalitis vaccine","volume":"30","author":"Sugawara","year":"2002","journal-title":"Biol J Int Assoc Biol Standard"},{"key":"10.1016\/j.vaccine.2018.01.075_b0045","unstructured":"Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. Morb Mortal Wkl Rept 2013;62:898\u2013900."},{"key":"10.1016\/j.vaccine.2018.01.075_b0050","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.vaccine.2012.01.054","article-title":"Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated)","volume":"30","author":"Kikukawa","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0055","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1016\/j.vaccine.2012.07.034","article-title":"Safety and immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (Inactivated) (JEBIK((R))V) in children","volume":"30","author":"Okada","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7774\/cevr.2012.1.1.3","article-title":"The history of vaccination and current vaccination policies in Korea","volume":"1","author":"Cha","year":"2012","journal-title":"Clin Exp Vaccin Res"},{"key":"10.1016\/j.vaccine.2018.01.075_b0065","unstructured":"KCDC. The Global status of vaccine development regarding Japanese encephalitis in Korea and other countries; 2011, December 9."},{"key":"10.1016\/j.vaccine.2018.01.075_b0070","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.4161\/hv.29743","article-title":"A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea","volume":"10","author":"Kim","year":"2014","journal-title":"Hum Vaccin Immunotherap"},{"key":"10.1016\/j.vaccine.2018.01.075_b0075","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.01.075_b0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1086\/590116","article-title":"Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine","volume":"198","author":"Tauber","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.075_b0085","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.vaccine.2008.05.081","article-title":"Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study","volume":"26","author":"Schuller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0090","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51","volume":"28","author":"Dubischar-Kastner","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0095","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.vaccine.2009.10.024","article-title":"Immunogenicity and safety of IXIARO (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age","volume":"28","author":"Kaltenbock","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/CVI.00377-13","article-title":"Phase III clinical trials comparing the immunogenicity and safety of the vero cell-derived Japanese encephalitis vaccine Encevac with those of mouse brain-derived vaccine by using the Beijing-1 strain","volume":"21","author":"Miyazaki","year":"2014","journal-title":"Clin Vaccin Immunol"},{"key":"10.1016\/j.vaccine.2018.01.075_b0105","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.vaccine.2011.01.058","article-title":"Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO\u00ae, IC51","volume":"29","author":"Eder","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0110","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1016\/j.vaccine.2015.05.037","article-title":"Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis","volume":"33","author":"Paulke-Korinek","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/cid\/cis542","article-title":"A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines","volume":"55","author":"Erra","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.01.075_b0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.vaccine.2013.10.055","article-title":"Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study","volume":"32","author":"Erra","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.01.075_b0125","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.vaccine.2014.11.046","article-title":"Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009\u20132012","volume":"33","author":"Rabe","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18301488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:03Z","timestamp":1759400763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18301488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0264410X18301488"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}